Literature DB >> 6301268

The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts.

H W Eckerson, J Romson, C Wyte, B N La Du.   

Abstract

A method for identifying two human serum paraoxonase phenotypes in vitro has been developed based upon the effect of NaCl upon paraoxonase activity. In a sample population of 336 individuals from the United States, 53.9% of the samples had serum paraoxonase that was highly stimulated (60%-257% above the control activity) by 1 M NaCl (salt-responsive), whereas the activity of the remaining samples was not salt-responsive (-23%-35%). The degree of stimulation was consistent and reproducible in frozen samples collected from an individual over a two-year period. Pedigree studies with 37 families indicate that the salt-responsive characteristic is inherited as a simple autosomal, Mendelian trait. Although the salt-responsive individuals on the average had a higher level of activity when assayed without added salt (basal activity) than did the non-salt-responsive individuals, there was considerable overlap in the basal paraoxonase activities. The quantitative polymorphism in serum paraoxonase activity observed in other laboratories is associated with a qualitative difference, quite possibly due to two distinct isozymic forms of the enzyme. A new designation for these alleles is proposed, and some preliminary studies on the molecular basis of the polymorphism are reported.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6301268      PMCID: PMC1685526     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  17 in total

1.  Genetic polymorphism and interethnic variability of plasma paroxonase activity.

Authors:  J R Playfer; L C Eze; M F Bullen; D A Evans
Journal:  J Med Genet       Date:  1976-10       Impact factor: 6.318

2.  Organophosphate splitting serum enzymes in different mammals.

Authors:  R Zech; K Zürcher
Journal:  Comp Biochem Physiol B       Date:  1974-07-15

3.  [On the specifity of human serum paraoxonase (author's transl)].

Authors:  M Geldmacher-von Mallinckrodt; M Pétényi; M Flügel; H Burgis; B Dietzel; H Metzner; H Nirschl; O Renner
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1973-03

4.  [Genetically determined polymorphism of human serum paraoxonase (EC 3.1.1.2)].

Authors:  H H Lindorf; M Petenyi; M Flügel; T Fischer; T Hiller
Journal:  Humangenetik       Date:  1973

5.  [Correlation between the observed variations in the inhibition of serum cholinesterase by E 600 and the activity of the enzyme system from human serum which cleaves E 600].

Authors:  W Baumgartner; M Pétenyi; H Burgis; H H Lindorf; H Metzner
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1972-02

6.  Serum arylesterase levels of activity in twins and their parents.

Authors:  N E Simpson
Journal:  Am J Hum Genet       Date:  1971-07       Impact factor: 11.025

7.  Hydrolysis of diethyl-p-nitrophenylphosphate and ethyl-p-nitrophenylethylphosphonate by human sera.

Authors:  M Skrinjarić-Spoljar; E Reiner
Journal:  Biochim Biophys Acta       Date:  1968-09-03

8.  On the genetics of the human serum paraoxonase (EC 3.1.1.2).

Authors:  M Geldmacher-v Mallinckrodt; G Hommel; J Dumbach
Journal:  Hum Genet       Date:  1979-09       Impact factor: 4.132

9.  The purification of the enzyme hydrolysing diethyl p-nitrophenyl phosphate (paraoxon) in sheep serum.

Authors:  A R MAIN
Journal:  Biochem J       Date:  1960-01       Impact factor: 3.857

10.  [On kinetics of the paraoxon hydrolysing enzyme in human serum (EC 3.1.1.2) (author's transl)].

Authors:  M Flügel; M Geldmacher-von Mallinckrodt
Journal:  Klin Wochenschr       Date:  1978-09-15
View more
  49 in total

1.  Distinction between 'A'-esterases and arylesterases. Implications for esterase classification.

Authors:  M I Mackness; H M Thompson; A R Hardy; C H Walker
Journal:  Biochem J       Date:  1987-07-01       Impact factor: 3.857

2.  Serum arylesterase and paraoxonase activity in patients with chronic hepatitis.

Authors:  Suleyman Sirri Kilic; Suleyman Aydin; Nermin Kilic; Fazilet Erman; Suna Aydin; Ilhami Celik
Journal:  World J Gastroenterol       Date:  2005-12-14       Impact factor: 5.742

Review 3.  The human serum paraoxonase/arylesterase polymorphism.

Authors:  B N La Du
Journal:  Am J Hum Genet       Date:  1988-09       Impact factor: 11.025

4.  Activity of esterases in plasma from Ghanaian and British subjects.

Authors:  F M Williams; E N Nicholson; N W Woolhouse; K K Adjepon-Yamoah; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

5.  Ameliorating effects of CAPE on oxidative damage caused by pneumoperitoneum in rat lung tissue.

Authors:  Isil Davarci; Harun Alp; Tumay Ozgur; Murat Karcioglu; Kasim Tuzcu; Osman Evliyaoglu; Sedat Motor; Tulin Durgun Yetim
Journal:  Int J Clin Exp Med       Date:  2014-07-15

Review 6.  Clinical significance of esterases in man.

Authors:  F M Williams
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

7.  Antioxidant potential, paraoxonase 1, ceruloplasmin activity and C-reactive protein concentration in diabetic retinopathy.

Authors:  Mariusz Nowak; Tomasz Wielkoszyński; Bogdan Marek; Beata Kos-Kudła; Elzbieta Swietochowska; Lucyna Siemińska; Jacek Karpe; Dariusz Kajdaniuk; Joanna Głogowska-Szelag; Katarzyna Nowak
Journal:  Clin Exp Med       Date:  2009-12-11       Impact factor: 3.984

8.  Relation of plasma protein oxidation parameters and paraoxonase activity in the ageing population.

Authors:  Ufuk Cakatay; Refik Kayali; Hafize Uzun
Journal:  Clin Exp Med       Date:  2008-04-03       Impact factor: 3.984

9.  Human paraoxonase 1 hydrolysis of nanomolar chlorpyrifos-oxon concentrations is unaffected by phenotype or Q192R genotype.

Authors:  R Hunter Coombes; Edward C Meek; Mary Beth Dail; Howard W Chambers; Janice E Chambers
Journal:  Toxicol Lett       Date:  2014-08-02       Impact factor: 4.372

10.  Evaluation of serum paraoxonase and arylesterase activities in ankylosing spondylitis patients.

Authors:  Fazile Hatipoglu Erdem; Saliha Karatay; Kadir Yildirim; Ahmet Kiziltunc
Journal:  Clinics (Sao Paulo)       Date:  2010-02       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.